Skip to main content
Erschienen in: Breast Cancer Research and Treatment 3/2019

04.01.2019 | Clinical trial

Extracapsular extension in the positive sentinel lymph node: a marker of poor prognosis in cT1-2N0 breast cancer patients?

verfasst von: Marissa L. G. Vane, Maria A. Willemsen, Lori M. van Roozendaal, Sander M. J. van Kuijk, Loes F. S. Kooreman, Sabine Siesling, Hans H. W. de Wilt, Marjolein L. Smidt

Erschienen in: Breast Cancer Research and Treatment | Ausgabe 3/2019

Einloggen, um Zugang zu erhalten

Abstract

Objective

This study aims to evaluate whether extracapsular extension (ECE) in the sentinel lymph node (SLN) is associated with involvement of ≥ 4 lymph node metastases at completion axillary lymph node dissection (ALND) and the effect on 5-year disease-free survival (DFS) and 10-year overall survival (OS).

Summary background data

ECE in a SLN is usually a contraindication for omitting completion ALND in cT1-2N0 breast cancer patients treated with breast-conserving therapy and 1–2 positive SLN(s).

Methods

All cT1-2N0 breast cancer patients with 1–3 positive SLN(s) who underwent ALND between 2005 and 2008 were selected from the Netherlands Cancer Registry. Logistic regression analysis was used to determine the association between ECE and ≥ 4 lymph node metastases. Five-year DFS and 10-year OS were analyzed using Kaplan–Meier survival analysis. Cox regression analysis was performed to correct for other prognostic factors.

Results

A total of 3502 patients were included. Information on ECE was available for 2111 (60.3%) patients, consisting of 741 (35.1%) patients with and 1370 (64.9%) without ECE. The incidence of ≥ 4 lymph node metastases was 116 (15.7%) in the ECE group vs. 80 (5.8%) in the group without ECE (p < 0.001). Five-year DFS rate was 86.4% in the ECE group compared to 88.8% in the group without ECE (p = 0.085). 10-year OS rate was 78.6% compared to 83.0% (p = 0.018), respectively. Cox regression analysis showed that ECE was not an independent prognostic factor for both DFS and OS.

Conclusions

ECE was significantly associated with involvement of ≥ 4 lymph node metastases in the completion ALND group. ECE was not an independent prognostic factor for both DFS and OS.
Anhänge
Nur mit Berechtigung zugänglich
Literatur
1.
Zurück zum Zitat Nottegar A, Veronese N, Senthil M, Roumen RM, Stubbs B, Choi AH et al (2016) Extra-nodal extension of sentinel lymph node metastasis is a marker of poor prognosis in breast cancer patients: a systematic review and an exploratory meta-analysis. Eur J Surg Oncol 42(7):919–925CrossRefPubMed Nottegar A, Veronese N, Senthil M, Roumen RM, Stubbs B, Choi AH et al (2016) Extra-nodal extension of sentinel lymph node metastasis is a marker of poor prognosis in breast cancer patients: a systematic review and an exploratory meta-analysis. Eur J Surg Oncol 42(7):919–925CrossRefPubMed
2.
Zurück zum Zitat Palamba HW, Rombouts MC, Ruers TJ, Klinkenbijl JH, Wobbes T (2001) Extranodal extension of axillary metastasis of invasive breast carcinoma as a possible predictor for the total number of positive lymph nodes. Eur J Surg Oncol 27(8):719–722CrossRefPubMed Palamba HW, Rombouts MC, Ruers TJ, Klinkenbijl JH, Wobbes T (2001) Extranodal extension of axillary metastasis of invasive breast carcinoma as a possible predictor for the total number of positive lymph nodes. Eur J Surg Oncol 27(8):719–722CrossRefPubMed
3.
Zurück zum Zitat Fujii T, Yanagita Y, Fujisawa T, Hirakata T, Iijima M, Kuwano H (2010) Implication of extracapsular invasion of sentinel lymph nodes in breast cancer: prediction of nonsentinel lymph node metastasis. World J Surg 34(3):544–548CrossRefPubMed Fujii T, Yanagita Y, Fujisawa T, Hirakata T, Iijima M, Kuwano H (2010) Implication of extracapsular invasion of sentinel lymph nodes in breast cancer: prediction of nonsentinel lymph node metastasis. World J Surg 34(3):544–548CrossRefPubMed
4.
Zurück zum Zitat van la Parra RF, Peer PG, Ernst MF, Bosscha K (2011) Meta-analysis of predictive factors for non-sentinel lymph node metastases in breast cancer patients with a positive SLN. Eur J Surg Oncol 37(4):290–299CrossRef van la Parra RF, Peer PG, Ernst MF, Bosscha K (2011) Meta-analysis of predictive factors for non-sentinel lymph node metastases in breast cancer patients with a positive SLN. Eur J Surg Oncol 37(4):290–299CrossRef
5.
Zurück zum Zitat Gorgulu S, Can MF, Yagci G, Sahin M, Tufan T (2007) Extracapsular extension is associated with increased ratio of metastatic to examined lymph nodes in axillary node-positive breast cancer. Clin Breast Cancer 7(10):796–800CrossRefPubMed Gorgulu S, Can MF, Yagci G, Sahin M, Tufan T (2007) Extracapsular extension is associated with increased ratio of metastatic to examined lymph nodes in axillary node-positive breast cancer. Clin Breast Cancer 7(10):796–800CrossRefPubMed
6.
Zurück zum Zitat Rivers AK, Griffith KA, Hunt KK, Degnim AC, Sabel MS, Diehl KM et al (2006) Clinicopathologic features associated with having four or more metastatic axillary nodes in breast cancer patients with a positive sentinel lymph node. Ann Surg Oncol 13(1):36–44CrossRefPubMed Rivers AK, Griffith KA, Hunt KK, Degnim AC, Sabel MS, Diehl KM et al (2006) Clinicopathologic features associated with having four or more metastatic axillary nodes in breast cancer patients with a positive sentinel lymph node. Ann Surg Oncol 13(1):36–44CrossRefPubMed
7.
Zurück zum Zitat Stitzenberg KB, Meyer AA, Stern SL, Cance WG, Calvo BF, Klauber-DeMore N et al (2003) Extracapsular extension of the sentinel lymph node metastasis: a predictor of nonsentinel node tumor burden. Ann Surg 237(5):607–612; discussion 12 – 3PubMedPubMedCentral Stitzenberg KB, Meyer AA, Stern SL, Cance WG, Calvo BF, Klauber-DeMore N et al (2003) Extracapsular extension of the sentinel lymph node metastasis: a predictor of nonsentinel node tumor burden. Ann Surg 237(5):607–612; discussion 12 – 3PubMedPubMedCentral
8.
Zurück zum Zitat Goyal A, Douglas-Jones A, Newcombe RG, Mansel RE, Group AT (2004) Predictors of non-sentinel lymph node metastasis in breast cancer patients. Eur J Cancer 40(11):1731–1737CrossRefPubMed Goyal A, Douglas-Jones A, Newcombe RG, Mansel RE, Group AT (2004) Predictors of non-sentinel lymph node metastasis in breast cancer patients. Eur J Cancer 40(11):1731–1737CrossRefPubMed
9.
Zurück zum Zitat Altinyollar H, Berberoglu U, Gulben K, Irkin F (2007) The correlation of extranodal invasion with other prognostic parameters in lymph node positive breast cancer. J Surg Oncol 95(7):567–571CrossRefPubMed Altinyollar H, Berberoglu U, Gulben K, Irkin F (2007) The correlation of extranodal invasion with other prognostic parameters in lymph node positive breast cancer. J Surg Oncol 95(7):567–571CrossRefPubMed
10.
Zurück zum Zitat Galimberti V, Cole BF, Zurrida S, Viale G, Luini A, Veronesi P et al (2013) Axillary dissection versus no axillary dissection in patients with sentinel-node micrometastases (IBCSG 23-01): a phase 3 randomised controlled trial. Lancet Oncol 14(4):297–305CrossRefPubMedPubMedCentral Galimberti V, Cole BF, Zurrida S, Viale G, Luini A, Veronesi P et al (2013) Axillary dissection versus no axillary dissection in patients with sentinel-node micrometastases (IBCSG 23-01): a phase 3 randomised controlled trial. Lancet Oncol 14(4):297–305CrossRefPubMedPubMedCentral
11.
Zurück zum Zitat Giuliano AE, Hunt KK, Ballman KV, Beitsch PD, Whitworth PW, Blumencranz PW et al (2011) Axillary dissection vs no axillary dissection in women with invasive breast cancer and sentinel node metastasis: a randomized clinical trial. JAMA 305(6):569–575CrossRefPubMedPubMedCentral Giuliano AE, Hunt KK, Ballman KV, Beitsch PD, Whitworth PW, Blumencranz PW et al (2011) Axillary dissection vs no axillary dissection in women with invasive breast cancer and sentinel node metastasis: a randomized clinical trial. JAMA 305(6):569–575CrossRefPubMedPubMedCentral
12.
Zurück zum Zitat Gooch J, King TA, Eaton A, Dengel L, Stempel M, Corben AD et al (2014) The extent of extracapsular extension may influence the need for axillary lymph node dissection in patients with T1-T2 breast cancer. Ann Surg Oncol 21(9):2897–2903CrossRefPubMedPubMedCentral Gooch J, King TA, Eaton A, Dengel L, Stempel M, Corben AD et al (2014) The extent of extracapsular extension may influence the need for axillary lymph node dissection in patients with T1-T2 breast cancer. Ann Surg Oncol 21(9):2897–2903CrossRefPubMedPubMedCentral
13.
Zurück zum Zitat van Roozendaal LM, de Wilt JH, van Dalen T, van der Hage JA, Strobbe LJ, Boersma LJ et al (2015) The value of completion axillary treatment in sentinel node positive breast cancer patients undergoing a mastectomy: a Dutch randomized controlled multicentre trial (BOOG 2013-07). BMC Cancer 15:610CrossRefPubMedPubMedCentral van Roozendaal LM, de Wilt JH, van Dalen T, van der Hage JA, Strobbe LJ, Boersma LJ et al (2015) The value of completion axillary treatment in sentinel node positive breast cancer patients undergoing a mastectomy: a Dutch randomized controlled multicentre trial (BOOG 2013-07). BMC Cancer 15:610CrossRefPubMedPubMedCentral
14.
Zurück zum Zitat Goyal A, Dodwell D (2015) POSNOC: a randomised trial looking at axillary treatment in women with one or two sentinel nodes with macrometastases. Clin Oncol (R Coll Radiol) 27(12):692–695CrossRef Goyal A, Dodwell D (2015) POSNOC: a randomised trial looking at axillary treatment in women with one or two sentinel nodes with macrometastases. Clin Oncol (R Coll Radiol) 27(12):692–695CrossRef
15.
Zurück zum Zitat Tinterri C, Canavese G, Bruzzi P, Dozin B (2016) SINODAR ONE, an ongoing randomized clinical trial to assess the role of axillary surgery in breast cancer patients with one or two macrometastatic sentinel nodes. Breast 30:197–200CrossRefPubMed Tinterri C, Canavese G, Bruzzi P, Dozin B (2016) SINODAR ONE, an ongoing randomized clinical trial to assess the role of axillary surgery in breast cancer patients with one or two macrometastatic sentinel nodes. Breast 30:197–200CrossRefPubMed
16.
Zurück zum Zitat Casparie M, Tiebosch AT, Burger G, Blauwgeers H, van de Pol A, van Krieken JH et al (2007) Pathology databanking and biobanking in The Netherlands, a central role for PALGA, the nationwide histopathology and cytopathology data network and archive. Cell Oncol 29(1):19–24PubMedPubMedCentral Casparie M, Tiebosch AT, Burger G, Blauwgeers H, van de Pol A, van Krieken JH et al (2007) Pathology databanking and biobanking in The Netherlands, a central role for PALGA, the nationwide histopathology and cytopathology data network and archive. Cell Oncol 29(1):19–24PubMedPubMedCentral
18.
Zurück zum Zitat Moossdorff M, van Roozendaal LM, Strobbe LJ, Aebi S, Cameron DA, Dixon JM et al (2014) Maastricht Delphi consensus on event definitions for classification of recurrence in breast cancer research. J Natl Cancer Inst 106(12):1–7CrossRef Moossdorff M, van Roozendaal LM, Strobbe LJ, Aebi S, Cameron DA, Dixon JM et al (2014) Maastricht Delphi consensus on event definitions for classification of recurrence in breast cancer research. J Natl Cancer Inst 106(12):1–7CrossRef
19.
Zurück zum Zitat Shigematsu H, Taguchi K, Koui H, Ohno S (2015) Clinical significance of extracapsular invasion at sentinel lymph nodes in breast cancer patients with sentinel lymph node involvement. Ann Surg Oncol 22(7):2365–2371CrossRefPubMed Shigematsu H, Taguchi K, Koui H, Ohno S (2015) Clinical significance of extracapsular invasion at sentinel lymph nodes in breast cancer patients with sentinel lymph node involvement. Ann Surg Oncol 22(7):2365–2371CrossRefPubMed
20.
Zurück zum Zitat Choi AH, Blount S, Perez MN, Chavez de Paz CE, Rodriguez SA, Surrusco M et al (2015) Size of extranodal extension on sentinel lymph node dissection in the American College of Surgeons Oncology Group Z0011 Trial Era. JAMA Surg 150(12):1141–1148CrossRefPubMed Choi AH, Blount S, Perez MN, Chavez de Paz CE, Rodriguez SA, Surrusco M et al (2015) Size of extranodal extension on sentinel lymph node dissection in the American College of Surgeons Oncology Group Z0011 Trial Era. JAMA Surg 150(12):1141–1148CrossRefPubMed
21.
Zurück zum Zitat Neri A, Marrelli D, Roviello F, De Stefano A, Guarnieri A, Pallucca E et al (2005) Prognostic value of extracapsular extension of axillary lymph node metastases in T1 to T3 breast cancer. Ann Surg Oncol 12(3):246–253CrossRefPubMed Neri A, Marrelli D, Roviello F, De Stefano A, Guarnieri A, Pallucca E et al (2005) Prognostic value of extracapsular extension of axillary lymph node metastases in T1 to T3 breast cancer. Ann Surg Oncol 12(3):246–253CrossRefPubMed
22.
Zurück zum Zitat Gruber G, Bonetti M, Nasi ML, Price KN, Castiglione-Gertsch M, Rudenstam CM et al (2005) Prognostic value of extracapsular tumor spread for locoregional control in premenopausal patients with node-positive breast cancer treated with classical cyclophosphamide, methotrexate, and fluorouracil: long-term observations from International Breast Cancer Study Group Trial VI. J Clin Oncol 23(28):7089–7097CrossRefPubMed Gruber G, Bonetti M, Nasi ML, Price KN, Castiglione-Gertsch M, Rudenstam CM et al (2005) Prognostic value of extracapsular tumor spread for locoregional control in premenopausal patients with node-positive breast cancer treated with classical cyclophosphamide, methotrexate, and fluorouracil: long-term observations from International Breast Cancer Study Group Trial VI. J Clin Oncol 23(28):7089–7097CrossRefPubMed
23.
Zurück zum Zitat Schipper RJ, van Roozendaal LM, de Vries B, Pijnappel RM, Beets-Tan RG, Lobbes MB et al (2013) Axillary ultrasound for preoperative nodal staging in breast cancer patients: is it of added value? Breast 22(6):1108–1113CrossRefPubMed Schipper RJ, van Roozendaal LM, de Vries B, Pijnappel RM, Beets-Tan RG, Lobbes MB et al (2013) Axillary ultrasound for preoperative nodal staging in breast cancer patients: is it of added value? Breast 22(6):1108–1113CrossRefPubMed
24.
Zurück zum Zitat Yajima R, Fujii T, Yanagita Y, Fujisawa T, Miyamoto T, Hirakata T et al (2015) Prognostic value of extracapsular invasion of axillary lymph nodes combined with peritumoral vascular invasion in patients with breast cancer. Ann Surg Oncol 22(1):52–58CrossRefPubMed Yajima R, Fujii T, Yanagita Y, Fujisawa T, Miyamoto T, Hirakata T et al (2015) Prognostic value of extracapsular invasion of axillary lymph nodes combined with peritumoral vascular invasion in patients with breast cancer. Ann Surg Oncol 22(1):52–58CrossRefPubMed
Metadaten
Titel
Extracapsular extension in the positive sentinel lymph node: a marker of poor prognosis in cT1-2N0 breast cancer patients?
verfasst von
Marissa L. G. Vane
Maria A. Willemsen
Lori M. van Roozendaal
Sander M. J. van Kuijk
Loes F. S. Kooreman
Sabine Siesling
Hans H. W. de Wilt
Marjolein L. Smidt
Publikationsdatum
04.01.2019
Verlag
Springer US
Erschienen in
Breast Cancer Research and Treatment / Ausgabe 3/2019
Print ISSN: 0167-6806
Elektronische ISSN: 1573-7217
DOI
https://doi.org/10.1007/s10549-018-05074-y

Weitere Artikel der Ausgabe 3/2019

Breast Cancer Research and Treatment 3/2019 Zur Ausgabe

Viel pflanzliche Nahrung, seltener Prostata-Ca.-Progression

12.05.2024 Prostatakarzinom Nachrichten

Ein hoher Anteil pflanzlicher Nahrung trägt möglicherweise dazu bei, das Progressionsrisiko von Männern mit Prostatakarzinomen zu senken. In einer US-Studie war das Risiko bei ausgeprägter pflanzlicher Ernährung in etwa halbiert.

Alter verschlechtert Prognose bei Endometriumkarzinom

11.05.2024 Endometriumkarzinom Nachrichten

Ein höheres Alter bei der Diagnose eines Endometriumkarzinoms ist mit aggressiveren Tumorcharakteristika assoziiert, scheint aber auch unabhängig von bekannten Risikofaktoren die Prognose der Erkrankung zu verschlimmern.

Darf man die Behandlung eines Neonazis ablehnen?

08.05.2024 Gesellschaft Nachrichten

In einer Leseranfrage in der Zeitschrift Journal of the American Academy of Dermatology möchte ein anonymer Dermatologe bzw. eine anonyme Dermatologin wissen, ob er oder sie einen Patienten behandeln muss, der eine rassistische Tätowierung trägt.

Erhöhte Mortalität bei postpartalem Brustkrebs

07.05.2024 Mammakarzinom Nachrichten

Auch für Trägerinnen von BRCA-Varianten gilt: Erkranken sie fünf bis zehn Jahre nach der letzten Schwangerschaft an Brustkrebs, ist das Sterberisiko besonders hoch.

Update Onkologie

Bestellen Sie unseren Fach-Newsletter und bleiben Sie gut informiert.